Survey Finds COVID-19 Disrupted Care, Well-being of Rare Disease Patients in Europe
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Articles by Marta Figueiredo, PhD
NurOwn Fails to Significantly Slow Disease Progression in ALS Patients, Top-line Data Show
BrainStorm Cell Therapeutics’ cell-based therapy NurOwn failed to significantly slow disease progression in people with rapidly progressing…
Bristol Myers Squibb Partners With Insitro to Develop New ALS Therapies
Bristol Myers Squibb has entered a five-year research collaboration with the machine learning startup insitro to discover…
Pivotal Trial Testing Multiple Therapies in ALS Now Enrolling at Third Scotland Site
MND-SMART, a pivotal platform trial designed to simultaneously test multiple treatment candidates in people with amyotrophic lateral sclerosis…
AMX0035 Significantly Extends ALS Patients’ Lives, Long-term Data Show
Treatment with AMX0035, Amylyx’s experimental oral therapy, significantly extends the lives of amyotrophic lateral sclerosis (ALS) patients…
$1.9M NIH Grant Supports Study of Ways to Preserve Swallowing, Breathing
The National Institutes of Health (NIH) has awarded a $1.9 million grant to University of Missouri (MU) researchers…
AMX0035 Safe, Effective in Slowing ALS Functional Decline, Trial Data Shows
Amylyx’s experimental oral treatment AMX0035 safely and effectively slows functional decline in amyotrophic lateral sclerosis (ALS) patients with rapidly progressing…
Pharnext’s PXT864 Shows Promising Neuroprotective Effects in ALS, Early Study Shows
Pharnext’s investigational oral combination therapy PXT864 prevents degeneration of motor neurons and their point of contact with…
NurOwn Promotes Immunoregulation, Lessens Inflammation, Preclinical Study Shows
BrainStorm Cell Therapeutics’ cell-based therapy NurOwn increases the number of immunosuppressive cells and lessens inflammation, according to a…
Phase 3 Update: Levosimendan Fails to Ease Breathing Problems in ALS Patients
Orion Corporation’s oral therapy levosimendan (ODM-109) failed to preserve lung function and overall functionality in people with amyotrophic…